STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:
Transgene (Paris:TNG) (Euronext: TNG) today announced that new pre-clinical data with two of its immunotherapy programs will be presented at the Annual Meeting of the American Association for Cancer Research (AACR) to be held in Philadelphia, Pennsylvania April 18-22, 2015.
A poster regarding TG4010, Transgene’s immunotherapy that is in late-stage clinical testing for non-small cell lung cancer, will be presented:
Immune checkpoint inhibitors enhance benefits of modified vaccinia virus Ankara to improve survival in preclinical models of cancer (Abstract #2497)
Session Category and Title: Immunology, Tumor Vaccines
Date and Time: Monday, April 20, 1:00-5:00 PM
Help employers find you! Check out all the jobs and post your resume.
